SynthesisBMC gastroenterology2026
Prophylactic hyperthermic intraperitoneal chemotherapy in patients with high-risk colorectal cancer with abdominal metastasis: a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeritoneal metastasis is a form of colorectal cancer metastasis associated a very poor prognosis. For patients at high risk of peritoneal metastasis, prophylactic hyperthermic intraperitoneal chemotherapy aims to eliminate subclinical lesions within the abdominal cavity to prevent recurrence; however, its clinical efficacy remains a subject of debate.
methodAccording to the PRISMA guidelines, studies comparing radical surgery combined with prophylactic HIPEC versus surgery alone in patients with high-risk colorectal cancer and peritoneal metastasis were systematically retrieved from PubMed, Embase, Cochrane Library and Web of Science databases. Randomized controlled trials and cohorts were included.Hazard ratios and their 95% confidence intervals were pooled using random-effects or fixed-effects models.
resultA total of 8 studies, involving 2,437 patients were included.The meta-analysis results indicated that combined prophylactic HIPEC significantly improved disease-free survival compared with surgery alone (HR = 0.80, 95%CI: 0.66–0.98, P = 0.028). However, there was no statistically significant difference in overall survival between the two groups (HR = 0.90, 95%CI: 0.64–1.27, P = 0.549). Sensitivity analysis confirmed the robustness of the results, and the heterogeneity among the included studies was low.
conclusionFor patients with colorectal cancer at high risk of abdominal metastasis, adding prophylactic HIPEC to radical surgery significantly improves disease-free survival, but no significant benefit in overall survival was observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.